Phase III begins for Olysio, Sovaldi hepatitis C combo
This article was originally published in Scrip
Executive Summary
Janssen and Medivir are enrolling patients in two Phase III clinical trials for an all-oral hepatitis C virus (HCV) regimen that combines the partners' NS3/4A protease inhibitor Olysio (simeprevir) with the Gilead Sciences nucleotide inhibitor Sovaldi (sofosbuvir).